title: Tazarotene gel, a new retinoid, for topical therapy of psoriasis: vehicle-controlled study of safety, efficacy, and duration of therapeutic effect.
abstract: BACKGROUND
  Topical therapy providing initial improvement and maintenance of effect after treatment of the large majority of patients with limited, mild to moderate psoriasis is not presently available. Previous topical retinoids have generally been either ineffective or too irritating for therapy of psoriasis.
  
  
  OBJECTIVE
  Our purpose was to evaluate a new topical retinoid, tazarotene, in the treatment of stable plaque psoriasis during treatment and posttreatment periods.
  
  
  METHODS
  In a double-blind manner, 324 patients were randomly selected to receive tazarotene 0.1% or 0.05% gel, or vehicle control, once daily for 12 weeks and were then followed up for 12 weeks after treatment.
  
  
  RESULTS
  Of the total, 318 patients could be evaluated. Tazarotene gels were superior (p < 0.05) to vehicle, often as early as treatment week 1, in all efficacy measures: plaque elevation, scaling, and erythema; treatment response; percentage treatment success (patients with > or = 50% improvement); and time to initial success. Efficacy was equivalent on target lesion sites (trunk or limbs and knees or elbows) and overall. A sustained therapeutic effect was observed for 12 weeks after treatment. Tazarotene gel was cosmetically acceptable. There was low systemic absorption, limiting toxicity to local irritation.
  
  
  CONCLUSIONS
  Once-daily tazarotene was effective and safe as a topical monotherapy for plaque psoriasis, providing rapid reduction of signs and symptoms.
authors.affiliation: Department of Dermatology, University of California Irvine, USA.
authors.forename: G D
authors.initials: GD
authors.lastname: Weinstein
authors.forename: G G
authors.initials: GG
authors.lastname: Krueger
authors.forename: N J
authors.initials: NJ
authors.lastname: Lowe
authors.forename: M
authors.initials: M
authors.lastname: Duvic
authors.forename: D J
authors.initials: DJ
authors.lastname: Friedman
authors.forename: B V
authors.initials: BV
authors.lastname: Jegasothy
authors.forename: J L
authors.initials: JL
authors.lastname: Jorizzo
authors.forename: E
authors.initials: E
authors.lastname: Shmunes
authors.forename: E H
authors.initials: EH
authors.lastname: Tschen
authors.forename: D A
authors.initials: DA
authors.lastname: Lew-Kaya
authors.forename: J C
authors.initials: JC
authors.lastname: Lue
authors.forename: J
authors.initials: J
authors.lastname: Sefton
authors.forename: J R
authors.initials: JR
authors.lastname: Gibson
authors.forename: R A
authors.initials: RA
authors.lastname: Chandraratna
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D004311:Double-Blind Method; D005260:Female; D005782:Gels; D006801:Humans; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000008:administration & dosage* / Q000009:adverse effects / Q000493:pharmacokinetics; D014677:Pharmaceutical Vehicles / Q000008:administration & dosage; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012176:Retinoids
chemical_list: D005782:Gels; D009539:Nicotinic Acids; D014677:Pharmaceutical Vehicles; C086827:tazarotene; D012176:Retinoids